

# OPTIMA HEALTH PLAN

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST

Directions: *The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-800-750-9692. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. Incomplete form will delay authorization process.*

**Drug Requested (please select one):**

**Topical Immunomodulators**

<input type="checkbox"/> <b>Zyclara® (imiquimod) 2.5% Pump</b>	<input type="checkbox"/> <b>Veregen® (sinecatechins) Ointment</b>
<input type="checkbox"/> <b>Zyclara® (imiquimod) 3.75% Packets/Pump</b>	<input type="checkbox"/> <b>Solaraze® (diclofenac) 3% Gel</b>

**DRUG INFORMATION:** Complete information below. If incomplete, authorization process will be delayed.

Drug Form/Strength: \_\_\_\_\_

Dosing Schedule: \_\_\_\_\_ Length of Therapy: \_\_\_\_\_

Diagnosis: \_\_\_\_\_ ICD Code, if applicable: \_\_\_\_\_

**CLINICAL CRITERIA:** ALL boxes **must** be checked to qualify or authorization process will be delayed..

**For Actinic Keratosis:**

(Both boxes **must** be checked)

- Patient has a diagnosis of actinic keratosis
- Requested product:
  - Zyclara® 2.5% Pump
  - Zyclara® 3.75% Packets/Pump
  - Solaraze® 3% Gel

**For External Genital and Perianal Warts/Condyloma Acuminata:**

(Two boxes **must** be checked)

- Patient has a diagnosis of external genital and/or perianal warts/condylomata acuminata

**AND**

- Patient has a documented trial and inadequate response or clinically significant adverse reaction to generic Aldara™ 5% cream (**submit chart notes**)

**OR**

- Patient has a documented trial and inadequate response or clinically significant adverse reaction to topical podofilox (**submit chart notes**)

**\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\***

**\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\***

Patient Name: \_\_\_\_\_

Member Optima #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

DEA OR NPI #: \_\_\_\_\_

\*Approved by Pharmacy and Therapeutics Committee: 8/20/2015  
REVISED/UPDATED: 10/23/2015; 12/22/2015; 12/20/2016; 8/19/2017.